|1.||Stockis, Armel: 6 articles (05/2015 - 07/2008)|
|2.||Johnson, Martin E: 3 articles (01/2014 - 01/2014)|
|3.||Lu, Sarah: 3 articles (01/2014 - 01/2014)|
|4.||Sargentini-Maier, Maria Laura: 3 articles (06/2013 - 07/2008)|
|5.||Niespodziany, Isabelle: 2 articles (12/2015 - 03/2015)|
|6.||Wolff, Christian: 2 articles (12/2015 - 03/2015)|
|7.||Watanabe, Shikiko: 2 articles (05/2015 - 01/2014)|
|8.||Labate, Angelo: 2 articles (01/2015 - 01/2015)|
|9.||De Sarro, Giovambattista: 2 articles (01/2015 - 01/2015)|
|10.||Gasparini, Sara: 2 articles (01/2015 - 01/2015)|
11/01/2015 - "Health-Related Quality of Life In Double-Blind Phase Iii Studies of Brivaracetam As Adjunctive Therapy of Partial-Onset Seizures."
08/01/2015 - "Adjunctive brivaracetam for patients with refractory partial seizures: A meta-analysis of randomized placebo-controlled trials."
08/01/2008 - "Recent phase II clinical trials demonstrating that brivaracetam is efficacious and well tolerated in the treatment of partial onset seizures have validated the strategy of the discovery programme. "
08/01/2015 - "To evaluate the clinical efficacy and safety of the newer antiepileptic drug (AED), brivaracetam (BRV), as adjunctive therapy for adults with refractory partial seizures. "
01/01/2015 - "Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures."
|2.||Myoclonus (Nocturnal Myoclonus)
01/01/2007 - "Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus."
01/01/2007 - "Both brivaracetam and levetiracetam significantly reduced auditory stimulated post-hypoxic myoclonus from a dose 0.3 mg/kg. At that dose, the anti-myoclonic activity of brivaracetam was already maximal whereas it continued to increase in a dose-relation manner with levetiracetam, suggesting that brivaracetam is a more potent agent. "
01/01/2007 - "In the present study, we evaluated the anti-seizure and anti-myoclonic activity of levetiracetam and brivaracetam in an established rat model of cardiac arrest-induced post-hypoxic myoclonus. "
01/01/2007 - "These findings demonstrate that brivaracetam possesses more potent anti-seizure and anti-myoclonic activity than levetiracetam in an established rat model of cardiac arrest-induced post-hypoxic myoclonus."
|3.||Dystonia (Limb Dystonia)
12/28/2008 - "Seletracetam (50 and 75 mg/kg i.p.) and brivaracetam (75 mg/kg i.p.) reduced the severity of dystonia to a comparable extent as levetiracetam (50 and 75 mg/kg i.p.). "
12/28/2008 - "Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster."
12/28/2008 - "In the present study, we examined the effects of the two new, high affinity SV2A ligands, brivaracetam and seletracetam, in comparison to levetiracetam on the severity of dystonia in mutant hamsters. "
01/01/2015 - "The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies."
09/04/2007 - "As such, investigations of the antiepileptic properties and tolerability of brivaracetam are warranted in further clinical studies of patients with epilepsy."
05/01/2015 - "Brivaracetam is a synaptic vesicle protein 2A ligand in phase III development for epilepsy. "
01/01/2015 - "Profile of brivaracetam and its potential in the treatment of epilepsy."
01/01/2015 - "This meta-analysis systematically assessed the efficacy and safety of different doses of brivaracetam (BRV) compared with placebo as adjunctive therapy for adults with partial-onset epilepsy. "
|4.||Sodium Channels (Sodium Channel)
|6.||2- (2- oxo- 4- propylpyrrolidin- 1- yl)butanamide (brivaracetam)
|1.||Induced Heart Arrest (Cardioplegia)